Once IPIX has licensed Brilacidin to a partner for a specific indication, can that partner market the drug with a name of their choosing or do they have to refer it as Brilacidin-OM, Brilacidin-IBD, Brilacidin-Crohn's, or some such name?

If IPIX was to license the entire Brilacidin platform to one BP, this would become a moot point because all their marketing across many medical indications would build the name recognition of B and IMO allow later indications to be accepted more quickly by the public. I see Humira currently following this marketing plan.

But if IPIX partners w/ multiple BPs, many may not want to do more than their fair share of marketing if all the others will benefit by doing very little. Feedback appreciated.

I personally would like to see the Brilacidin name out there in print, TV, etc as often as possible.